DOI: 10.1002/ame2.12097
Epalrestat improves motor symptoms by reducing oxidativestress and inflammation in the reserpine induced mouse model of Parkinson's disease
Md. Mahbubur Rahman
Rupali Rani Chakraborti
Md. Abdullah Potol
Ariful Haque Abir
Ozayra Sharmin
Mahabub Alam
Md. Fazlur Rahman Khan
Rownock Afrin
Humayra Jannat
Rasiqh Wadud
Zaki Farhad Habib
1.Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health & Life Sciences, North South University,Dhaka, Bangladesh2.Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health & Life Sciences, North South University,Dhaka, Bangladesh3.Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health & Life Sciences, North South University,Dhaka, Bangladesh4.Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health & Life Sciences, North South University,Dhaka, Bangladesh5.Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health & Life Sciences, North South University,Dhaka, Bangladesh6.Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health & Life Sciences, North South University,Dhaka, Bangladesh7.Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health & Life Sciences, North South University,Dhaka, Bangladesh8.Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health & Life Sciences, North South University,Dhaka, Bangladesh9.Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health & Life Sciences, North South University,Dhaka, Bangladesh10.Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health & Life Sciences, North South University,Dhaka, Bangladesh11.Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health & Life Sciences, North South University,Dhaka, Bangladesh
摘要：Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder af-fecting a large number of elderly people worldwide. The current therapies for PD are symptom-based; they do not provide a cure but improve the quality of life. Muscular dysfunction is the hallmark clinical feature of PD and oxidative stress and inflamma-tion play a critical role in its pathogenesis. Epalrestat is used for the treatment of dia-betic neuropathy and is known to improve antioxidative defense mechanisms in the CNS. Therefore, in this study, we investigated the role of Epalrestat in the reserpine induced mouse model of PD. Method: We used Swiss Albino mice for the PD model and tested for akinesia/brad-ykinesia, muscular rigidity, palpebral ptosis, and tremor, as well as conducting swim and open field tests. Brain samples were used to determine oxidative stress param-eters and infiltration of immune cells. Results: Epalrestat treatment significantly improved akinesia and bradykinesia, muscular dysfunctions, tremor level, and gait functions compared to the reserpine group. It also improved the latency in the swim test. Eplarestat significantly reduced lipid peroxidation and NO concentration in different brain tissues and increased the activity of antioxidative enzymes, glutathione, catalase, and superoxide dismutase. Furthermore, Epalrestat reduced neuroinflammation by reducing the number of in-filtrating immune cells. Conclusion: Eplarestat improves muscular dysfunction in PD by reducing oxidative stress and inflammation.
机标关键词：
论文发表日期：2020-03-25
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：13( 9-21 )
英文信息